Brivaracetam | UCB 34714 | CAS#357336-20-0

MedKoo Cat#: 326678 | Name: Brivaracetam

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Brivaracetam is discontinued (DEA controlled susbtance). Brivaracetam, also known as UCB 34714, is a chemical analog of levetiracetam, is a racetam derivative with anticonvulsant (antiepileptic) properties approved for the treatment of epilepsy. Brivaracetam was approved in 2/18/2016 to treat partial onset seizures in patients age 16 years and older with epilepsy. This product is a controlled substance.

Chemical Structure

Brivaracetam

CAS#357336-20-0

Theoretical Analysis

MedKoo Cat#: 326678

Name: Brivaracetam

CAS#: 357336-20-0

Chemical Formula: C11H20N2O2

Exact Mass: 212.1525

Molecular Weight: 212.29

Elemental Analysis: C, 62.24; H, 9.50; N, 13.20; O, 15.07

Price and Availability

This product was removed for the commercial reasons.

Related CAS #

No Data

Synonym

UCB 34714; UCB-34714; UCB34714; Briviact; Brivaracetam.

IUPAC/Chemical Name

(2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide

InChi Key

MSYKRHVOOPPJKU-BDAKNGLRSA-N

InChi Code

InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1

SMILES Code

CC[C@H](N1C(C[C@@H](CCC)C1)=O)C(N)=O

Appearance

White to off-white solid powder

Purity

>99% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 212.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Steinhoff BJ, Bacher M, Blickhan M, Bernedo V, Dietmann D, Intravooth T, Kornmeier R, Kurth C, Mahn P, Schneider M, Stockinger J, Staack AM. Is brivaracetam-induced elevation of carbamazepine-epoxide levels common and clinically relevant? - A case series. Epilepsy Res. 2019 Nov 6;159:106236. doi: 10.1016/j.eplepsyres.2019.106236. [Epub ahead of print] PubMed PMID: 31743818. 2: Fonseca E, Guzmán L, Quintana M, Abraira L, Santamarina E, Salas-Puig X, Toledo M. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy. Epilepsy Behav. 2019 Nov 12;102:106657. doi: 10.1016/j.yebeh.2019.106657. [Epub ahead of print] PubMed PMID: 31731108. 3: Nissenkorn A, Tzadok M, Bar-Yosef O, Ben-Zeev B. Treatment with brivaracetam in children - The experience of a pediatric epilepsy center. Epilepsy Behav. 2019 Dec;101(Pt A):106541. doi: 10.1016/j.yebeh.2019.106541. Epub 2019 Nov 4. PubMed PMID: 31698260. 4: Menzler K, Mross PM, Rosenow F, Schubert-Bast S, Willems LM, Zahnert F, Immisch I, Fuest S, von Podewils F, Kunz R, Hirsch M, Mueller T, Marquetand J, Winter Y, Langenbruch L, Cicanic M, Beyenburg S, Strzelczyk A, Knake S. First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study. BMJ Open. 2019 Nov 4;9(11):e030746. doi: 10.1136/bmjopen-2019-030746. PubMed PMID: 31690606. 5: Lafortune J, Deacon C, Clément JF. Brivaracetam: first Canadian experience in an intractable epilepsy population. Can J Neurol Sci. 2019 Nov 5:1-18. doi: 10.1017/cjn.2019.321. [Epub ahead of print] PubMed PMID: 31685045. 6: Moseley BD, Otoul C, Staelens L, Stockis A. Pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with focal seizures: Pooled analysis of data from randomized clinical trials. Epilepsy Res. 2019 Dec;158:106218. doi: 10.1016/j.eplepsyres.2019.106218. Epub 2019 Oct 14. PubMed PMID: 31675621. 7: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548532/ PubMed PMID: 31643850. 8: McGuire S, Silva G, Lal D, Khurana DS, Legido A, Hasbani D, Carvalho KS, Melvin J, Valencia I. Safety and Efficacy of Brivaracetam in Pediatric Refractory Epilepsy: A Single-Center Clinical Experience. J Child Neurol. 2019 Oct 16:883073819879276. doi: 10.1177/0883073819879276. [Epub ahead of print] PubMed PMID: 31617449. 9: Tsymbalyuk S, Smith M, Gore C, Tsymbalyuk O, Ivanova S, Sansur C, Gerzanich V, Simard JM. Brivaracetam attenuates pain behaviors in a murine model of neuropathic pain. Mol Pain. 2019 Jan-Dec;15:1744806919886503. doi: 10.1177/1744806919886503. PubMed PMID: 31615323. 10: Feyissa AM. Brivaracetam in the treatment of epilepsy: a review of clinical trial data. Neuropsychiatr Dis Treat. 2019 Sep 9;15:2587-2600. doi: 10.2147/NDT.S143548. eCollection 2019. PubMed PMID: 31571877; PubMed Central PMCID: PMC6750854. 11: Steinhoff BJ, Staack AM. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Ther Adv Neurol Disord. 2019 Sep 9;12:1756286419873518. doi: 10.1177/1756286419873518. eCollection 2019. Review. PubMed PMID: 31523280; PubMed Central PMCID: PMC6734620. 12: Foo EC, Geldard J, Peacey C, Wright E, Eltayeb K, Maguire M. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability. Epilepsy Behav. 2019 Oct;99:106505. doi: 10.1016/j.yebeh.2019.106505. Epub 2019 Sep 4. PubMed PMID: 31493736. 13: Brigo F, Lattanzi S, Nardone R, Trinka E. Intravenous Brivaracetam in the Treatment of Status Epilepticus: A Systematic Review. CNS Drugs. 2019 Aug;33(8):771-781. doi: 10.1007/s40263-019-00652-0. Review. PubMed PMID: 31342405. 14: Willems LM, Bauer S, Rosenow F, Strzelczyk A. Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus. Expert Opin Pharmacother. 2019 Oct;20(14):1755-1765. doi: 10.1080/14656566.2019.1637420. Epub 2019 Jul 2. Review. PubMed PMID: 31264486. 15: Santamarina E, Parejo Carbonell B, Sala J, Gutiérrez-Viedma Á, Miró J, Asensio M, Abraira L, Falip M, Ojeda J, López-González FJ, Rodríguez-Osorio X, Mauri JÁ, Aiguabella M, García Morales I, Toledo M. Use of intravenous brivaracetam in status epilepticus: A multicenter registry. Epilepsia. 2019 Aug;60(8):1593-1601. doi: 10.1111/epi.16094. Epub 2019 Jul 1. PubMed PMID: 31260101. 16: Liu E, Dilley D, McDonough B, Stockis A, Daniels T. Safety and Tolerability of Adjunctive Brivaracetam in Pediatric Patients < 16 Years with Epilepsy: An Open-Label Trial. Paediatr Drugs. 2019 Aug;21(4):291-301. doi: 10.1007/s40272-019-00332-y. PubMed PMID: 31250322; PubMed Central PMCID: PMC6682562. 17: Klotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J. Effects of cannabidiol on brivaracetam plasma levels. Epilepsia. 2019 Jul;60(7):e74-e77. doi: 10.1111/epi.16071. Epub 2019 Jun 18. PubMed PMID: 31211851. 18: Makke Y, Abou-Khalil B. Brivaracetam efficacy and safety in focal epilepsy. Expert Rev Neurother. 2019 Oct;19(10):955-964. doi: 10.1080/14737175.2019.1631160. Epub 2019 Jun 24. PubMed PMID: 31195850. 19: Toledo M, Abraira L, Mazuela G, Quintana M, Cazorla S, Santamarina E. Effect of brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study. Seizure. 2019 Jul;69:198-203. doi: 10.1016/j.seizure.2019.04.021. Epub 2019 May 1. PubMed PMID: 31079028. 20: Hellerslia V, Asistido JM, Iyamu A. Brivaracetam for epilepsy. JAAPA. 2019 May;32(5):21-22. doi: 10.1097/01.JAA.0000554748.77547.f8. PubMed PMID: 31033711.